This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01328/identifier/chebi/
n17http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/drug/DB01328/identifier/pharmgkb/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01328/identifier/kegg-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/drugbank/drug/DB01328/identifier/drugbank/
n10http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01328
rdf:type
n3:Drug
n3:description
A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections. [PubChem]
n3:group
approved
n3:halfLife
4.5 hours
n3:indication
For the treatment of bacterial infections caused by susceptible microorganisms.
owl:sameAs
n15:DB01328 n17:DB01328
dcterms:title
Cefonicid
adms:identifier
n6:DB01328 n7:C06882 n8:3491 n13:PA164743021
n3:mechanismOfAction
Cefonicid, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins.
n3:synonym
Cefonicido (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Cefonicid Cefonicidum
n3:proteinBinding
98% bound to plasma proteins.
n3:synthesisReference
Theodore John Polansky, "Crystalline benzathine salt of cefonicid and its preparation." U.S. Patent US5705496, issued October, 1992.
n11:hasConcept
n12:M0024188
n3:IUPAC-Name
n4:271B3EE2-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3EE8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3EE7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3EE4-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3EE5-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3EE6-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3EE0-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3EE1-363D-11E5-9242-09173F13E4C5 n4:271B3EDE-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3EDF-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:J01DC06
n3:H-Bond-Acceptor-Count
n4:271B3EEE-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3EEF-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3EE9-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3EEA-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3EEC-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3EEB-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3EED-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
61270-58-4
n3:category
n3:Bioavailability
n4:271B3EF4-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3EF6-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3EF7-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3EF3-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3EF2-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3EF5-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3EE3-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B3EF0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B3EF1-363D-11E5-9242-09173F13E4C5